Jan Wehkamp

Jan Wehkamp

Auto-generated profile, based on publicly available information

Jan Wehkamp

Department of Internal Medicine I, University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2012 in Gut
Verified
Journal Article
Closed access
PDF file
WHWolfgang Hueber
Wolfgang Hueber
BSBruce E Sands
Bruce E Sands
SLSteve Lewitzky
Steve Lewitzky
MVMarc Vandemeulebroecke
Marc Vandemeulebroecke
WRWalter Reinisch
Walter Reinisch
FGfor the Secukinumab in Crohn's Disease Study Group
for the Secukinumab in Crohn's Disease Study Group
Objective The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. Design In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥220 to ≤450) were assigned in a 2:1 ratio to 2×10 mg/kg intravenous secukinumab or placebo. The primary end point, addressed by Bayesian statistics augmented with historical placebo information, was the probability that secukinumab reduces the CDAI by ≥50 points more than placebo at week 6. Ancillary analyses explored associations of 35 candidate genetic polymorphisms and faecal calprotectin response. Results 59 patients (39 secukinumab, 20 placebo, mean baseline CDAI 307 and 301, respectively) were recruited. 18/59 (31%) patients discontinued prematurely (12/39 (31%) secukinumab, 6/20 (30%) placebo), 10/59 (17%) due to insufficient therapeutic effect (8/39 (21%) secukinumab, 2/20 (10%) placebo). Fourteen serious adverse events occurred in 10 patients (seven secukinumab, three placebo); 20 infections, including four local fungal infections, were seen on secukinumab versus none on placebo. Primary end point analysis estimated <0.1% probability (∆CDAI (SD) =33.9 (19.7), 95% credible interval −4.9 to 72.9) that secukinumab reduces CDAI by ≥50 points more than placebo. Secondary area under the curve analysis (weeks 4–10) showed a significant difference (mean ΔCDAI=49; 95% CI (2 to 96), p=0.043) in favour of placebo. Post hoc subgroup analysis showed that unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers (CRP≥10 mg/l and/or faecal calprotectin≥200 ng/ml; mean ΔCDAI=62; 95% CI (−1 to 125), p=0.054 in favour of placebo). Absence of the minor allele of tumour necrosis factor-like ligand 1A was strongly associated with lack of response measured by baseline-adjusted changes in calprotectin at week 6 (p=0.00035 Bonferroni-corrected). Conclusions Blockade of IL-17A was ineffective and higher rates of adverse events were noted compared with placebo. Clinical trial registration This trial was registered at ClinicalTrial.gov with the number NCT01009281.

5 December 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JWJan Wehkamp
Jan Wehkamp
NSNita H. Salzman
Nita H. Salzman
EPEdith Porter
Edith Porter
SNSabine Nuding
Sabine Nuding
MWMichael Weichenthal
Michael Weichenthal
CBCharles Bevins
Charles Bevins
The pathogenesis of Crohn′s disease (CD), an idiopathic inflammatory bowel disease, is attributed, in part, to intestinal bacteria that may initiate and perpetuate mucosal inflammation in genetically susceptible individuals. Paneth cells (PC) are the major source of antimicrobial peptides in the small intestine, including human α-defensins HD5 and HD6. We tested the hypothesis that reduced expression of PC α-defensins compromises mucosal host defenses and predisposes patients to CD of the ileum. We report that patients with CD of the ileum have reduced antibacterial activity in their intestinal mucosal extracts. These specimens also showed decreased expression of PC α-defensins, whereas the expression of eight other PC products either remained unchanged or increased when compared with controls. The specific decrease of α-defensins was independent of the degree of inflammation in the specimens and was not observed in either CD of the colon, ulcerative colitis, or pouchitis. The functional consequence of α-defensin expression levels was examined by using a transgenic mouse model, where we found changes in HD5 expression levels, comparable to those observed in CD, had a pronounced impact on the luminal microbiota. Thus, the specific deficiency of PC defensins that characterizes ileal CD may compromise innate immune defenses of the ileal mucosa and initiate and/or perpetuate this disease.

11 October 2004 in Gut
Verified
Journal Article
Open access
PDF file
JWJ Wehkamp
J Wehkamp
JHJ Harder
J Harder
MWM Weichenthal
M Weichenthal
Matthias SchwabMatthias Schwab
Matthias Schwab
ESE Schäffeler
E Schäffeler
ESEduard Stange
Eduard Stange
Background: Mutations in NOD2, a putative intracellular receptor for bacterial peptidoglycans, are associated with a subset of Crohn’s disease but the molecular mechanism linking this protein with the disease pathogenesis remains unclear. Human α defensins (HD-5 and HD-6) are antibiotic effector molecules predominantly expressed in Paneth cells of the ileum. Paneth cells also express NOD2. To address the hypothesis that the function of NOD2 may affect expression of Paneth cell defensins, we compared their expression levels with respect to NOD2 mutations in Crohn’s disease. Methods: Forty five Crohn’s disease patients (24 with NOD2 mutations, 21 with wild-type NOD2) and 12 controls were studied. Real time reverse transcription-polymerase chain reaction was performed with mucosal mRNA for HD-5, HD-6, lysozyme, secretory phospholipase A 2 (sPLA 2 ), tumour necrosis factor α, interleukin 8, and human hypoxanthine phosphoribosyltransferase (housekeeping gene). Immunohistochemistry with anti-HD-5 and histological Paneth cell staining were performed in 10 patients with NOD2 mutations or wild-type genotypes. Results: Ileal expression of HD-5 and HD-6, but not sPLA 2 or lysozyme, were diminished in affected ileum, and the decrease was significantly more pronounced in patients with NOD2 mutations. In the colon, HD-5, HD-6, and sPLA 2 were increased during inflammation in wild-type but not in NOD2 mutated patients. In both the colon and ileum, proinflammatory cytokines and lysozyme were unaffected by NOD2 status. Immunohistochemistry identified Paneth cells as the sole source of HD-5. Conclusion: As alpha defensins are important in the mucosal antibacterial barrier, their diminished expression may explain, in part, the bacterial induced mucosal inflammation and ileal involvement of Crohn’s disease, especially in the case of NOD2 mutations.

27 July 2012 in Science
Verified
Journal Article
Closed access
PDF file
HCHiutung Chu
Hiutung Chu
MPMarzena Pazgier
Marzena Pazgier
GJGrace Jung
Grace Jung
SNSean-Paul Nuccio
Sean-Paul Nuccio
PCPatricia A. Castillo
Patricia A. Castillo
CBCharles Bevins
Charles Bevins
Netting the Bad Guys: Antimicrobial peptides are an evolutionarily conserved component of innate immunity in the intestine. One family, α-defensins, typically exert their antimicrobial effects through microbicidal activity against bacteria. Humans express only two α-defensins, human defensin 5 (HD5) and HD6. HD5 exhibits bactericidal activity and plays a role in shaping the bacterial composition of the gut. HD6, on the other hand, does not show bactericidal activity and its function in the gut is unclear. Now, Chu et al. (p. 477 , published online 21 June; see the Perspective by Ouellette and Selsted ) show that HD6 protects against bacterial pathogens. Rather than killing them directly, HD6 binds to bacteria surface proteins and, through a process of self-assembly, forms fibrils and nanonets that ensnare invading bacterial pathogens.

19 January 2011 in Nature
Verified
Journal Article
Closed access
PDF file
BSBjoern O. Schroeder
Bjoern O. Schroeder
ZWZhihong Wu
Zhihong Wu
SNSabine Nuding
Sabine Nuding
SGSandra Groscurth
Sandra Groscurth
MMMoritz Marcinowski
Moritz Marcinowski
JWJan Wehkamp
Jan Wehkamp

1 September 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KFKlaus Fellermann
Klaus Fellermann
DSDaniel E. Stange
Daniel E. Stange
ESElke Schaeffeler
Elke Schaeffeler
HSHartmut Schmalzl
Hartmut Schmalzl
JWJan Wehkamp
Jan Wehkamp
ESEduard F. Stange
Eduard F. Stange